0.4703  -0.001 (-0.15%)		07-26 16:00
Open: 0.485 High: 0.4899 Volume: 309,949		Pre. Close: 0.471 Low: 0.453 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.68	1-year :	0.8
Resists	First :	0.58	Second :	0.68
Pivot price	0.49
Supports	First :	0.4	Second :	0.34
MAs	MA(5) :	0.46	MA(20) :	0.5
	MA(100) :	0.83	MA(250) :	1.35
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	25.9	D(3) :	24.1
RSI	RSI(14): 34
52-week	High :	3.89	Low :	0.4

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ENVB ] has closed above bottom band by 31.9%. Bollinger Bands are 67.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.49 - 0.49	0.49 - 0.5
Low:	0.45 - 0.45	0.45 - 0.45
Close:	0.46 - 0.47	0.47 - 0.48

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Thu, 25 Jul 2024
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally - StockTitan

Mon, 15 Jul 2024
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - Business Wire

Mon, 15 Jul 2024
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - StockTitan

Wed, 10 Jul 2024
Enveric Biosciences Announces Patent Granted for Drug Candidate - Business Wire

Tue, 14 May 2024
Enveric signs deal with MindBio - Green Market Report

Wed, 08 May 2024
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids - Microdose Psychedelic Insights

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	8 (M)
Held by Insiders	3.4 (%)
Held by Institutions	6.3 (%)
Shares Short	152 (K)
Shares Short P.Month	338 (K)

EPS	-6.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.88
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-71.2 %
Return on Equity (ttm)	-168.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.08
PEG Ratio	0
Price to Book value	0.52
Price to Sales	0
Price to Cash Flow	-0.33

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.